Identifying simple, low9cost and scalable means of supporting lifestyle change and medication adherence for patients following a cardiovascular event is important.
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# The TEXTMEDS study aims to investigate whether a cardiac education and support program sent via mobile phone text message improves medication adherence and risk factor levels in patients following an acute coronary syndrome (ACS).
A single blind, multicentre, randomised clinical trial of 1400 patients after an ACS with 12 months follow9up. The intervention group will receive multiple weekly text messages that provide information, motivation, support to adhere to medications, quit smoking (if relevant), and recommendations for healthy diet and exercise. The primary endpoint is the percentage of patients who are adherent to cardioprotective medications and the key secondary outcomes are mean systolic blood pressure and LDL9cholesterol.
Secondary outcomes will also include total cholesterol, mean diastolic blood pressure, the percentage of participants who are adherent to each cardioprotective medication class, the percentage of participants who achieve target levels of cardiovascular risk factors, major vascular events, hospital readmissions and all9cause mortality. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost9 effectiveness.
The study will provide multi9centre randomised trial evidence of the effects of a text9message based program on cardioprotective medication adherence and levels of cardiovascular risk factors. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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This is a multi9centre trial that will provide the evidence for effectiveness of text messaging programs and their generalisability above existing trial evidence from single centre studies.
The intervention development follows a previously published process, the messages are based on psychological behaviour change theory and the message management is via a custom9built computerised program.
Alongside this study we have included an economic evaluation study and process evaluation.
This is a study conducted across multiple centre of Australia only and uses English text only.
The primary and key secondary study outcomes are surrogate outcomes measures and not hard clinical outcomes measures such as major adverse cardiovascular events.
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 to9face interview and at six months by phone. Further data will be obtained via extraction of linked data available with consent from government repositories. The study will be augmented by formal economic and process evaluations to assess acceptability, utility and cost9 effectiveness of the intervention. This study will be monitored and managed centrally with periodic site monitoring visits.
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After obtaining written informed consent, the data are entered by the site coordinator into a Patients with a confirmed diagnosis of ACS are eligible for the study. ACS is defined based on one of the two following criteria;
1. Acute myocardial infarction consistent with the 3 rd Universal definition of MI (26):
Detection of rise and/or fall of cardiac troponin with at least one value above the 99 th percentile of the upper reference limit together with evidence of myocardial The control group will receive standard care post9ACS as determined by their usual doctors.
This generally includes secondary prevention cardiovascular medications and referral to a centre9based cardiac rehabilitation or other secondary prevention program.
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The intervention group will receive standard care (as described above), plus an additional support package that includes a series of text messages focusing on medication adherence and The text message intervention builds upon our previous experience in developing text9 message interventions from the TEXT ME study. (17) We have previously described the process of message content development, (27) as well as the details of the intervention and its delivery, including the similarities and differences of the TEXT ME and TEXTMEDS study in a separate manuscript. (28) For TEXTMEDS, the majority of text messages providing information and support on lifestyle modification are from the TEXT ME study, (17) Each message will have a unique signature (study and hospital name) to ensure that participants know these messages are from the TEXTMEDS study and participants at and is given specific training to respond to patients' requests and provide further guidance using an intervention manual we have developed for the study. The health counsellor is assisted as required by a clinical research fellow (cardiologist or cardiology sub9specialty trainee and clinicians from the study investigator team). All replies and responses are reviewed in regular weekly team meetings.
The TEXTMEDS message management system is a more sophisticated version of the original TEXT ME software program used to deliver the TEXT ME intervention. In brief, it uses a web interface to enable the simultaneous entry of data from multiple study centres.
Key participant characteristics are automatically imported from electronic databases into the The follow9up study assessments will occur at six months by phone and 12 months in9person. The key secondary outcomes are the difference between intervention and control groups at 12 months for LDL9cholesterol level and systolic blood pressure (raised blood pressure). Other secondary outcomes include: total cholesterol, diastolic blood pressure, the proportion of participants adherent to each medication class, other cardiovascular risk factors including behavioural risk factors, psychosocial factors, major cardiovascular events, hospital readmissions and all9cause mortality and composites of risk factor control and major adverse The process evaluation will include a semi9quantitative survey and focus groups with intervention participants. All participants receiving the intervention will be invited to complete a written questionnaire assessing their perceptions, experience and the degree of engagement with the intervention at the completion of the trial. The questionnaire will comprise a combination of closed 59point Likert scale and open questions. A sample of the intervention group participants will be invited to participate in focus groups on perceptions of anticipate approximately four focus groups will be needed. An in9depth interview will also be conducted with the health counsellor to understand his/her perceptions of patients' engagement with the program. Focus groups and the health counsellor interview will be conducted by a trained qualitative interviewer, digitally recorded and transcribed. Analyses will be thematic and coding based on emergent themes.
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The costs and health outcomes associated with the intervention will be compared in an incremental cost9effectiveness analysis. A health sector perspective will be adopted. The costs of delivering the intervention will be assessed by measuring and valuing the incremental resources used.(39) Hospitalisations will be collected at each follow9up. Consent will be sought for access to individual participant Medical Benefits Schedule and Pharmaceutical Benefits Scheme claims usage through Medicare Australia to ascertain use of medical services and prescribed pharmaceuticals. Changes to health benefits will be assessed using Quality Adjusted Life Years (QALYs). These will be assessed using the SF912_V2™ Health Survey(36) (License Number QM024287). Although we do not expect significant differences in survival or quality of life between treatment groups within trial, these data are needed to provide an estimate of the baseline quality of life in this patient population. Given the likely small numbers of cardiovascular events occurring within the trial, the quality of life and costs data collected will need to be modelled using data on quality of life and cost associated with cardiovascular events from literature review. (40) Long terms costs and QALYs will be modelled using a decision analytic Markov model that will enable us to 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 A 10% improvement in the proportion taking appropriate secondary prevention is considered to be a clinically meaningful increase and associated with a decrease in short9term mortality. (42) To test for a 10% improvement in the primary outcome (RR of 1.10) in the treatment compared to the control arm (assuming ~70% of patients are taking appropriate secondary prevention in control arm, based on contemporary Australian registry data, (43, 44) and this would rise to 77% in the intervention arm) with 80% power (type I error = 5%, two9
sided test), we would require a total sample size of 1246, rising to ~ 1396 accounting for a ~10% loss to follow up. This sample size of 1246 would enable us to also detect with 80% power a minimum detectable difference in secondary outcomes of i) 0.15 mmol/L in LDL9 cholesterol assuming a standard deviation (SD) of 0.92mmol/L,(45) ii) 2.7 mmHg in systolic blood pressure, assuming a SD of 17mmHg(45) and a minimum detectable relative risk of 0.69 in CV events assuming a major CV event rate of 19% or a power of approximately 13%
to detect a relative risk of 0.80 in CV events, assuming a lower CV event rate of 5% at 12 months from contemporary Austalian data.
The intention to treat principle will be used and patients will be analyzed according to the group to which they are allocated. A detailed statistical analysis plan will be prepared prior to the analysis. The primary outcome will be compared between groups using the chi9square
test. The primary analysis will be unadjusted. The mean level of blood pressure and cholesterol will be analyzed using an analysis of covariance using the baseline values as the We will also analyze effects across subgroups, such as sex and age, using logistic regression models with treatment group, subgroup and subgroup by treatment interaction as fixed effects. Number of patients with major cardiovascular events will be compared between treatments using a chi9square test. The criterion for statistical significance will be set at α =0.05. Number needed to treat (NNT) will also be calculated and its 95% CI for the primary outcome.
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reported measures can overestimate adherence, but this should not impact the difference in adherence between the intervention and control groups. To get an objective measure of the impact of the intervention, key outcomes for this trial will also be LDL9cholesterol and blood pressure, which are both strong and objective measures of cardiovascular risk. We will also be examining the impact of the intervention program on behavioural risk factors, which our predecessor study to this, TEXT ME, demonstrated a substantial impact. In our previous single9centre study -TEXT ME, our group has demonstrated that a lifestyle9 focused text9messaging program was associated with reductions in LDL9cholesterol, blood pressure, body mass index (BMI) and smoking, and with increases of physical activity levels.
TEXT ME also demonstrated that participants in the intervention group were more likely to achieve risk factor control for multiple risk factors with 28.9% in the intervention, versus 10.3% in the control group achieving target levels of 4 or more key risk factors (RR 2.80, 95% CI, 1.95 -4.02). (17) The TEXTMEDS study will extend the knowledge from the TEXT ME study by examining the impact of a longer text9message program (12 months versus six months) and delivered across multiple urban and rural hospitals in a range of socioeconomically varied contexts across the breadth of Australia. By involving a health counsellor to track and respond to messages, TEXTMEDS will also provide information on whether interactivity is regarded as important by participants.
A cardiac prevention program delivered via text messages has the advantages of low cost and being easily automated. These elements can allow these programs to reach large numbers of people, including those in resource9poor settings and in geographically isolated communities, and therefore, the potential to have a substantial population impact.
In conclusion, the TEXTMEDS study will provide multi9centre randomised controlled data on whether a cardiac prevention program delivered to support cardiac prevention across multiple hospital sites is of utility and effective in improving targets of cardiac prevention in patients post9 ACS. 
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The organisations that supported this work (through peer9reviewed, educational research grants) had no role in study conception, data collection, analysis and interpretation, and writing of the manuscript.
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